Company intelligence

CLNN

Clene Inc. · NASDAQ · Healthcare

Price$3.29+6.13% · +$0.19

Market cap46.76MEquity value

P / E-0.9Trailing ratio

Volume88.39KLatest session

Market data

CLNN price chart

TradingView

Related signals

1 min delayed

Browse public CLNN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CLNNMay 4, 2026+2.73% since signal

Clene Secures FDA Review for ALS Treatment, Catalyzing Market Interest

Clene's CNM-Au8 has received FDA agreement for New Drug Application review, potentially under accelerated approval based on neurofilament light data. This news, coupled with their planned Phase 3 study commencing in early 2027, may significantly boost investor sentiment and stock performance.

View signal analysis

CLNNMay 8, 2024+5.51% since signal

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

- Clene Inc. reported a quarterly loss of $0.09 per share, missing revenue estimates. - Clene shares have risen 32% year-to-date, outperforming the S&P 500. - Mixed earnings outlook for Clene, with a Zacks Rank #3 (Hold) predicting market performance. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings

View signal analysis

Research